Our skin is the barrier through which we interact with the world. When that barrier has problems, it can often be an indication of other med

Castle Biosciences, Inc. announced today the pricing of its IPO of 4,000,000 shares of its common stock at a price of $16/share

Cristina Griffin Joins Or-Genix Therapeutics as Chief Business Officer

Castle Biosciences filed on Wednesday with the SEC to raise up to $58 million in an initial public offering.

The definition of old is becoming increasingly fluid. There is no typical ‘old’ any longer.

Over the past decade, skin health has evolved to become a complex, deep and diverse category that touches a huge portion of the population.

Partnership melds firms' commitment to innovation in dermatology and patient-centric approach.

Gore Range Capital today announced that its first fund is closed to new investors